1,162,986 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Bought by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,162,986 shares of the company's stock, valued at approximately $13,758,000. Gilder Gagnon Howe & Co. LLC owned approximately 0.16% of Roivant Sciences as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Treasurer of the State of North Carolina grew its stake in Roivant Sciences by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock worth $2,213,000 after acquiring an additional 1,170 shares during the period. GAMMA Investing LLC boosted its holdings in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares during the period. WINTON GROUP Ltd grew its holdings in Roivant Sciences by 1.5% during the 4th quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock valued at $1,095,000 after purchasing an additional 1,332 shares in the last quarter. Covestor Ltd increased its position in shares of Roivant Sciences by 7.5% during the fourth quarter. Covestor Ltd now owns 20,634 shares of the company's stock worth $245,000 after acquiring an additional 1,444 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after buying an additional 1,507 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Roivant Sciences Stock Down 0.2 %

ROIV stock traded down $0.02 during mid-day trading on Thursday, reaching $11.60. 3,184,167 shares of the stock traded hands, compared to its average volume of 5,474,376. The business has a 50-day moving average of $10.38 and a two-hundred day moving average of $11.14. The firm has a market capitalization of $8.28 billion, a PE ratio of -77.29 and a beta of 1.25. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,116,345 shares in the company, valued at approximately $11,409,045.90. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock valued at $14,922,538 in the last quarter. Company insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.